Glenmark Sets Up Clinical R&D Unit At Oxford As Drug Pipeline Swells
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Glenmark Pharmaceuticals, one of India's fastest growing research-based drug companies, has set up a new clinical research and development outfit at Oxford Science and Business Park in the United Kingdom
You may also be interested in...
Almirall’s Loss of Aclidinium Could Be Glenmark’s Gain
MUMBAI - Hopes for oglemilast, Glenmark's chronic obstructive pulmonary disease candidate being developed by U.S.-based Forest Laboratories brightened after rival experimental drug aclidinium - also licensed by Forest - showed disappointing results in Phase III studies
Lilly Halts Development of Glenmark’s TRVP-1 Receptor Antagonist
MUMBAI - Glenmark Pharmaceuticals suffered a major blow to its drug discovery plans as Eli Lilly, its research partner for the development of pain management compound GRC 6211 suspended further clinical development on the experimental drug
Lilly Halts Development of Glenmark’s TRVP-1 Receptor Antagonist
MUMBAI - Glenmark Pharmaceuticals suffered a major blow to its drug discovery plans as Eli Lilly, its research partner for the development of pain management compound GRC 6211 suspended further clinical development on the experimental drug